THRX Initiated With Overweight At Piper Jaffray
Analysts at Piper Jaffray initiate coverage of Theravance (NASDAQ: THRX) with an "overweight" rating. The target price for THRX is set to $16.
TRRX gained 1.81% to close at $12.97 on Friday. More Analyst Ratings here
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.